At this high-impact session, global experts from Delos Capital, A*STAR, Kuder Consulting, and ICON Biotech unpacked key trends shaping the future: from N-of-1 personalized medicine, to modular mRNA manufacturing, and precision-targeted ADC drugs.

Key Takeaways:
Eric Huang: Multi-tool editing & novel payment models are paving the way for "One Person, One Therapy"
Boon Tong Koh: Singapore leads with a modular, continuous mRNA platform revolution
MannChing Ku: 100 years of ADC evolution shows stability & payload design are critical
Dela Cruz: Clinical realities of ADCs—navigating toxicity, dosing & targeting hurdles

The future of medicine is personal, modular, and highly targeted.

Full article: https://reurl.cc/axnA2Y
#Globalbio #BIOAsiaTaiwan #Nof1 #PersonalizedMedicine #mRNA #ADC #BiotechInnovation #PrecisionTherapy #NextGenMedicine